Jan. 27 at 12:40 PM
$RNAZ Financial Status and Risks
Despite the good news, the following data should be noted:
Dilution and Capital Raising: The company has made several capital raisings in the past year to finance the expensive experiments. Last October, it even acquired Polynoma with the help of strategic financing of
$25 million.
Extreme Volatility: The stock is still considered very high risk. In a 52-week period, it fell from record prices of hundreds of dollars (following a share consolidation - Reverse Split) to single-digit prices. Good luck to our company.
